share_log

Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target

Moomoo 24/7 ·  Mar 21 06:53

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment